LexFinance Announced a Favorable Partial Award in a US$ 28 Billion Arbitration Against Brazil and for the Benefit of Petrobras
25.11.2020 16:00:00 EET | Business Wire | Press release
LexFinance announced a favorable partial award in a US$ 28 billion arbitration against Brazil and for the benefit of Petrobras.
The claim has been filed by a minority shareholder of Petrobras against the Brazilian Government for the economic losses suffered by Petrobras due to corruption practices disclosed in the Car Wash investigation and caused by the abuse of power of the Brazilian Government as controlling shareholder of Petrobras.
The partial award recognized the arbitrability of the dispute, that the Brazilian Government is subject to the arbitration clause and the standing of the claimant funded by LexFinance to act on behalf and for the benefit of Petrobras.
If the damages are confirmed in the last phase of the arbitration expected to conclude during 2021, the Brazilian Government will have to compensate Petrobras for losses currently estimated at US$ 28 billion. In addition, according to article 246 of the Brazilian Corporate Law, it will have to pay to the claimant funded by LexFinance 5% of any compensation received by Petrobras, plus attorney’s fees to the law firms in charge of the claim, which may increase the total amount to be paid to US$ 35 billion.
The arbitration is being conducted before the Arbitration Chamber of the Brazilian Stock Exchange (BM&F-BOVESPA).
TozziniFreire and Barbosa, Müssnich & Aragão are the two Brazilian law firms representing the claimant in the legal procedures related to the claim. Berkeley Research Group (BRG) is the international damages expert firm that estimated the damages suffered by Petrobras.
About LexFinance
LexFinance is an asset manager specialized in structuring and funding arbitration claims in Iberoamerica and worldwide. Founded in 2015, LexFinance offers financing solutions to the arbitration market using equity, debt and special situations strategies both in the primary and secondary market of legal claims.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201125005357/en/
Contact information
Heitor Castro, Daniel Febrero, 55-1-246-6217
heitor.castro@lex-finance.com
daniel.febrero@lex-finance.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Amazfit Announces the T-Rex Ultra 2: a Titanium GPS Watch Engineered for the Extreme19.2.2026 14:00:00 EET | Press release
Amazfit, a leading global smart wearable brand owned by Zepp Health, today announced the T-Rex Ultra 2, the latest and most advanced member of its rugged T-Rex lineup. As part of the T-Rex family, the T-Rex Ultra 2 is built for uncertainty—designed to remain reliable in conditions where plans, environments, and outcomes are never fully defined. Purpose-built for extreme environments, the T-Rex Ultra 2 combines premium materials, enhanced navigation capabilities, and extended battery life to support athletes and explorers tackling long, complex routes where preparation and reliability matter most. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260219679075/en/ Amazfit Announces the T-Rex Ultra 2: a Titanium GPS Watch Engineered for the Extreme “With the T-Rex Ultra 2, we focused on building a watch for people who rely on navigation, endurance, and on-watch decision-making in demanding environments,” said Scott Shepley, Head o
YolTech Therapeutics Announces Positive Interim Data on YOLT-202 for the Treatment of Alpha-1 Antitrypsin Deficiency19.2.2026 13:00:00 EET | Press release
YolTech Therapeutics, a late clinical-stage biotechnology company developing in vivo gene editing therapies, today announced positive interim data from an investigator-initiated trial (IIT) of YOLT-202, the Company’s investigational in vivo base editing therapy, for the treatment of Alpha-1 Antitrypsin Deficiency (AATD) that demonstrated positive safety and tolerability as well as meaningful increases in AAT levels in evaluated patients treated with the 35 mg and 45 mg dose levels. “These interim findings mark an exciting and important milestone for YolTech and for patients living with severe AATD. The rapid, robust, and dose‑dependent increases in functional AAT levels observed in this study—particularly among individuals with the PiZZ genotype—underscore the transformative potential of in vivo base editing as a one‑time treatment approach,” stated Yuxuan Wu, M.D., Founder and CEO of YolTech Therapeutics. “Equally encouraging is the favorable safety profile we have seen to date, which
Infobip Recognized as RCS for Business Leader by Juniper Research19.2.2026 12:15:00 EET | Press release
Global cloud communications platform Infobip has been named the number one Established Leader in the Juniper Research RCS for Business 2026 Leaderboard. The analyst firm scored Infobip as the top vendor out of 17 because of its superior capability and capacity, enhanced product and position and significant market presence. Juniper Research scores vendors on a range of factors including but not limited to their geographical reach, depth of partnerships, RCS value-added services, notable RCS deployments, and innovation. According to Juniper Research, Infobip stands out for its wide network of mobile operator connections for RCS for Business and its extensive geographic reach, including being the first provider to launch RCS messaging across all major US telecom carriers. Brands such as Virgin Atlantic are using Infobip’s RCS solutions to deliver interactive, conversational messaging that drives stronger customer engagement. Molly Gatford, Senior Research Analyst, Juniper Research, said:“
Serviceplan Group Deploys Creative AI Across Global Operations in Partnership With Luma AI19.2.2026 12:00:00 EET | Press release
Serviceplan Group today announced a strategic partnership with Luma AI to deploy AI for creative work across the agency group’s global operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260219346568/en/ Serviceplan Group today announced a strategic partnership with Luma AI to deploy AI for creative work across the agency group’s global operations. Shown here (L-R) Alex Schill, Global Chief Creative Officer of Serviceplan Group, Jason Day, Head of EMEA for Luma AI, Amit Jain, Co-Founder and CEO of Luma AI, and Florian Haller, CEO of Serviceplan Group. Under the agreement, Luma AI will serve as Serviceplan Group’s AI technology partner, embedding AI for creative work into professional workflows spanning strategy, creative development, content production, and delivery. The rollout marks a significant operational milestone for Serviceplan Group, positioning it as the first of the world’s largest agency groups to standard
GekkoVet and Royal Canin Enter Latin America with Mexico Launch, Opening a New Continent in their Global Partnership19.2.2026 11:59:00 EET | Press release
GekkoVet, the Finnish leader in AI-powered clinical decision support for veterinarians, and Royal Canin, a global pioneer in pet health through nutrition, announce the launch of their strategic collaboration in Mexico. This marks the first national rollout of their partnership in Latin America, expanding the initiative that began earlier this year with successful deployments in Asia. Royal Canin Mexico is equipping veterinary teams with GekkoVet’s intelligent platform, which provides real-time diagnostic assistance, treatment recommendations, and drug information. The collaboration aims to enhance clinical efficiency, improve patient outcomes, and support veterinarians with evidence-based tools that integrate seamlessly into daily practice. “This launch in Mexico is a major step forward—not just regionally, but globally,” said Johanna Majamaa, DVM and co-founder of GekkoVet. “After strong momentum in Asia, entering Latin America opens a new chapter in our mission to empower veterinaria
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom